

Xiaoyan Si

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8576029/publications.pdf>

Version: 2024-02-01

44
papers

507
citations

759233

12
h-index

752698

20
g-index

58
all docs

58
docs citations

58
times ranked

693
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thoracic Cancer, 2020, 11, 191-197. | 1.9 | 52 |
| 2 | Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese <scp>NSCLC</scp> patients. Thoracic Cancer, 2020, 11, 1621-1632. | 1.9 | 44 |
| 3 | Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Thoracic Cancer, 2019, 10, 551-556. | 1.9 | 42 |
| 4 | Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. Lung Cancer, 2018, 125, 142-149. | 2.0 | 34 |
| 5 | Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2018, 122, 32-37. | 2.0 | 32 |
| 6 | Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. Thoracic Cancer, 2020, 11, 799-804. | 1.9 | 24 |
| 7 | Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thoracic Cancer, 2020, 11, 810-818. | 1.9 | 19 |
| 8 | Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. Thoracic Cancer, 2020, 11, 1647-1654. | 1.9 | 18 |
| 9 | Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. Lung Cancer, 2018, 122, 1-6. | 2.0 | 17 |
| 10 | Management of immune checkpoint inhibitor-related dermatologic adverse events. Thoracic Cancer, 2020, 11, 488-492. | 1.9 | 17 |
| 11 | Genomic characteristics of driver genes in <scp>Chinese</scp> patients with non-small cell lung cancer. Thoracic Cancer, 2021, 12, 357-363. | 1.9 | 15 |
| 12 | Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. Thoracic Cancer, 2020, 11, 594-602. | 1.9 | 14 |
| 13 | Use of glucocorticoids in the management of immunotherapy-related adverse effects. Thoracic Cancer, 2020, 11, 3047-3052. | 1.9 | 13 |
| 14 | Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. Thoracic Cancer, 2020, 11, 1746-1751. | 1.9 | 11 |
| 15 | Opportunistic infections complicating immunotherapy for non-small cell lung cancer. Thoracic Cancer, 2020, 11, 1689-1694. | 1.9 | 11 |
| 16 | Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. Cancer Medicine, 2021, 10, 188-198. | 2.8 | 11 |
| 17 | Management of immune checkpoint inhibitor-related adverse events: A review of case reports. Thoracic Cancer, 2020, 11, 498-504. | 1.9 | 10 |
| 18 | Histologic transformation of lung cancer during pembrolizumab therapy: A case report. Thoracic Cancer, 2020, 11, 793-796. | 1.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. Thoracic Cancer, 2020, 11, 475-480. | 1.9 | 9 |
| 20 | Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thoracic Cancer, 2020, 11, 805-809. | 1.9 | 8 |
| 21 | Immune checkpoint inhibitor-related epidermal necrolysis: A rare condition with poor prognosis. European Journal of Cancer, 2021, 145, 194-196. | 2.8 | 8 |
| 22 | Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. Thoracic Cancer, 2018, 9, 1056-1061. | 1.9 | 7 |
| 23 | EGFR T790M detection in formalin-fixed paraffin-embedded tissues of patients with lung cancer using RNA-based in situ hybridization: A preliminary feasibility study. Thoracic Cancer, 2019, 10, 1936-1944. | 1.9 | 7 |
| 24 | <p>NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score</p>. Cancer Management and Research, 2020, Volume 12, 5975-5985. | 1.9 | 7 |
| 25 | A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096584. | 3.2 | 7 |
| 26 | The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.. Journal of Clinical Oncology, 2017, 35, e20613-e20613. | 1.6 | 7 |
| 27 | Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. OncoTargets and Therapy, 2018, Volume 11, 7513-7519. | 2.0 | 6 |
| 28 | Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. Thoracic Cancer, 2020, 11, 1216-1223. | 1.9 | 5 |
| 29 | Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. Thoracic Cancer, 2020, 11, 829-834. | 1.9 | 5 |
| 30 | Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. Thoracic Cancer, 2020, 11, 1099-1104. | 1.9 | 5 |
| 31 | Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period. Thoracic Cancer, 2022, 13, 539-548. | 1.9 | 5 |
| 32 | <p>Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease</p>. OncoTargets and Therapy, 2019, Volume 12, 5545-5549. | 2.0 | 4 |
| 33 | Non-small-cell lung cancer with <sc>ERBB2</sc> mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report. Thoracic Cancer, 2021, 12, 1244-1247. | 1.9 | 4 |
| 34 | Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases. Thoracic Cancer, 2020, 11, 2339-2342. | 1.9 | 3 |
| 35 | Management of immune checkpoint inhibitor-related rheumatic adverse events. Thoracic Cancer, 2020, 11, 198-202. | 1.9 | 2 |
| 36 | Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. Thoracic Cancer, 2022, 13, 1059-1066. | 1.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Pulmonary and Skeletal Infection of <i>Mycobacterium kansasii</i> . American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1169-1170. | 5.6 | 1 |
| 38 | Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. Thoracic Cancer, 2020, 11, 2077-2086. | 1.9 | 1 |
| 39 | Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. Thoracic Cancer, 2020, 11, 1869-1875. | 1.9 | 1 |
| 40 | Safety and efficacy of cetuximab combined with chemotherapy in Chinese patients with advanced non-small cell lung cancer. Thoracic Cancer, 2012, 3, 188-193. | 1.9 | 0 |
| 41 | Myocarditis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.. Journal of Clinical Oncology, 2021, 39, e14579-e14579. | 1.6 | 0 |
| 42 | The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. Journal of Clinical Oncology, 2015, 33, e19070-e19070. | 1.6 | 0 |
| 43 | Rebiopsy status among non-small cell lung cancer patients after Icotinib therapy in China.. Journal of Clinical Oncology, 2018, 36, e21146-e21146. | 1.6 | 0 |
| 44 | Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 small cell lung cancer: A phase II study.. Journal of Clinical Oncology, 2022, 40, 8573-8573. | 1.6 | 0 |